Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ESK440: sourced facts only. name: "Given the potential roles of ALK and FAK in NB, we evaluated the efficacy of a novel compound ESK440, which is a dual ALK and FAK inhibitor." [DOI:10.1158/1538-7445.am2022-2018]; target: "Given the potential roles of ALK and FAK in NB, we evaluated the efficacy of a novel compound ESK440, which is a dual ALK and FAK inhibitor." [DOI:10.1158/1538-7445.am2022-2018]; target: "Given the potential roles of ALK and FAK in NB, we evaluated the efficacy of a novel compound ESK440, which is a dual ALK and FAK inhibitor." [DOI:10.1158/1538-7445.am2022-2018]; developer: "1University of Michigan, Ann Arbor, MI." [DOI:10.1158/1538-7445.am2022-2018]; stage: "Intriguingly, ESK440 studies in NB xenograft model (NB-1) resulted in tumor regression in treated animals." [DOI:10.1158/1538-7445.am2022-2018]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ESK440.